Trial Profile
An Open-label, Randomized Clinical Trial of Recombinant Human Endostatin (Endo) Combined With Chemotherapy Compared With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Endostatin (Primary) ; Nedaplatin (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Sep 2018 New trial record